Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2

Newly emerging SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. By using live virus assays, we assessed the ex vivo inhibition of the B.1 wild-type (WT), delta and omicron BA.1 and BA.2 lineages by post-infusion sera from 40 individuals treated with bamlanivimab/etese...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiaschi, Lia, Dragoni, Filippo, Schiaroli, Elisabetta, Bergna, Annalisa, Rossetti, Barbara, Giammarino, Federica, Biba, Camilla, Gidari, Anna, Lai, Alessia, Nencioni, Cesira, Francisci, Daniela, Zazzi, Maurizio, Vicenti, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321742/
https://www.ncbi.nlm.nih.gov/pubmed/35891355
http://dx.doi.org/10.3390/v14071374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321742/
https://www.ncbi.nlm.nih.gov/pubmed/35891355
http://dx.doi.org/10.3390/v14071374

Ejemplares similares